AI and machine learning are shaping up drug discovery and it is about time. The old way- slow, expensive and full of dead-ends- are outdated. Tools like deep learning, graph neural networks, GANs and reinforcement learning are stepping up. These tools actually help scientists spot new targets, sift through virtual libraries for promising compounds, predict how molecules will behave, dream up brand new drug designs, find fresh uses for old drugs and even streamline clinical trials. Graph models, in particular, shine because they get the complicated shape and connections in molecules. These all let researchers simulate how tiny structures interact in the messy reality of biology. Generative AI pushes boundaries even further by designing all sorts of molecules- each tailored for certain properties- across an almost endless chemical universe. Technology is making and creating waves everywhere: cancer, heart conditions, brain disorders, infections-you name it. Across the board, the results are better predictions, smarter trade-offs, more molecular variety and a smoother path from lab to clinic. Of course, it’s not all smooth sailing. Challenges remain like messy data, black-box designing making, regulatory headaches and the tricky business of converting code into medicine. But even with those bumps, AI-powered drug discovery isn’t another upgrade. It is a real-shift: more data-driven, more scalable and a lot more personal. The evidence keeps piling up-AI is speeding up therapeutic breakthroughs and rewriting the future position of medicine, one algorithm at a time.

With 29 studies in front of us, one thing stands out: Artificial Intelligence is shaking up drug discovery in a big way. Researchers are using machine learning, deep learning, generative models, and graph models to zero in on drug targets, screen compounds faster, predict molecular properties, design new drugs from scratch, and even repurpose old ones. Graph Neural Networks and generative models deserve a special mention—they capture more detailed snapshots of molecules and help scientists sift through huge chemical spaces efficiently. Plus, they let researchers juggle things like effectiveness, safety, and how easy a drug is to make, all at once. These studies dive into a range of diseases—heart problems, brain disorders, cancer, infections—and show just how much potential AI has to change the way we develop new treatments. Still, there are hurdles. Data quality is a big one, and so is figuring out why these models make the predictions they do. It’s also tough to make sure an AI tool that works in a lab will work just as well in the real world, and then there’s the question of meeting strict regulations. Even with these challenges, it’s clear the field is moving away from old-school trial and error and toward smarter, data-driven drug development. For AI to truly deliver on the promise of faster, more personalized medicine, researchers need to push for better explainability, tougher benchmarks, and seamless end-to-end pipelines. That’s how we unlock the real power of AI in medicine.

[1]A. U. Rehman et al., “Role of Artificial Intelligence in Revolutionizing Drug Discovery,” Fundamental Research, 2025. [2]D. R. Serrano et al., “Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine,” Pharmaceutics, 2024. [3]S. Vatansever et al., “Artificial Intelligence and Machine Learning-Aided Drug Discovery in Central Nervous System Diseases: State-of-the-Arts and Future Directions,” Medicinal Research Reviews, 2021. [4]X. Yang et al., “Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery,” Chemical Reviews, 2019. [5]C. Cerchia and A. Lavecchia, “New Avenues in Artificial-Intelligence-Assisted Drug Discovery,” Drug Discovery Today, 2023. [6]O. Zhang et al., “Graph Neural Networks in Modern AI-Aided Drug Discovery,” 2025. [7] M. Abbasi et al., “Designing Optimized Drug Candidates with Generative Adversarial Network,” Journal of Cheminformatics, 2022. [8]I. Kalansuriya et al., “AI-Driven Innovations in Cardiovascular Drug Development,” Journal of Population Therapeutics & Clinical Pharmacology, 2024. [9]Z. Fang et al., “Recent Developments in GNNs for Drug Discovery,” arXiv, 2025. [10]Khera et al., “Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice,” 2024. [11]Sabry et al., “AI-Driven Drug Discovery and Repurposing Using Multi-Omics for Myocardial Infarction and Heart Failure,” 2025. [12]D’Souza et al., “Deep Learning-Based Modeling of Drug–Target Interaction Prediction Incorporating Binding Site Information,” 2023. [13]Conte et al., “Artificial Intelligence-Assisted Drug and Biomarker Discovery for Glioblastoma: A Scoping Review,” 2025. [14]Ray Das et al., “Application of Artificial Intelligence (AI) in Pharmaceutical Industry: In-Depth Review,” 2025. [15]Sudan et al., “Artificial Intelligence in Drug Discovery,” 2020. [16]Jarallah et al., “Artificial Intelligence Revolution in Drug Discovery: A Paradigm Shift in Pharmaceutical Innovation,” 2025. [17]Carracedo-Reboredo et al., “A Review on Machine Learning Approaches and Trends in Drug Discovery,” 2021. [18]Nguyen et al., “GraphDTA: Predicting Drug–Target Binding Affinity with Graph Neural Networks,” 2020. [19]Tripathi et al., “Recent Advances and Application of Generative Adversarial Networks in Drug Discovery, Development, and Targeting,” Artificial Intelligence in the Life Sciences, 2022. [20]Hasselgren and Oprea, “Artificial Intelligence for Drug Discovery: Are We There Yet?” Annual Review of Pharmacology and Toxicology, 2024. [21]“Applications of Artificial Intelligence in Drug Repurposing,” 2025. [22]“PLASMOpred: A Machine Learning-Based Web Application for Predicting Antimalarial Small Molecules,” 2025. [23]“Transforming Cardiovascular Care with Artificial Intelligence: From Discovery to Practice,” 2024. [24]“AI-Driven Drug Discovery and Repurposing Using Multi-Omics,” 2025. [25]“Deep Learning-Based Drug–Target Interaction Prediction,” 2023. [26]“Artificial Intelligence-Assisted Drug and Biomarker Discovery for Glioblastoma,” 2025. [27]“Graph Neural Networks in Modern AI-Aided Drug Discovery,” 2025. [28]“AI Driven Drug Discovery: Breaking Barriers in Pharmaceutical Research and Development,” 2020.

© 2025 International Journal of Engineering and Techniques (IJET).

Digital Object Identifier (DOI)

IJET assigns a unique DOI to every accepted article via Zenodo for persistent linking and citation. Your article’s DOI: https://doi.org/{{doi}}

Open DOI About Zenodo DOI

Close